Hypoxia-inducible factor 1-alpha–Beta-secretase 1–Vascular endothelial growth factor axis (HIF-1α–BACE1–VEGF axis)

The Hypoxia / HIF-1α–BACE1–VEGF axis is a regulatory signaling pathway where hypoxia stabilizes Hypoxia-inducible factor 1-alpha (HIF-1α), which subsequently upregulates the expression of Beta-secretase 1 (BACE1) and Vascular endothelial growth factor (VEGF) (Sun et al., 2006, PNAS; Zhang et al., 2007, Neurobiol Aging). This axis is particularly significant in Alzheimer's disease, as hypoxia-induced BACE1 elevation increases the production of amyloid-beta (Aβ) peptides, while VEGF promotes angiogenesis and vascular permeability (Guglielmotto et al., 2009, J Neurochem). In oncology, this axis facilitates tumor adaptation to low-oxygen environments by promoting both metabolic shifts and blood vessel formation (Masoud & Li, 2015, J Hematol Oncol). Therapeutic targeting involves BACE1 inhibitors like Verubecestat for neurodegeneration and VEGF inhibitors like Bevacizumab for cancer and macular degeneration (Vassar et al., 2014, J Neurochem). However, clinical trials for BACE1 inhibitors have faced challenges due to lack of efficacy in late-stage disease and safety concerns regarding cognitive side effects (Knopman, 2019, Alzheimers Dement).

Other names

HIF-1α/BACE1/VEGF signaling pathwayHypoxia-mediated neurovascular axisHIF-1α-BACE1-VEGF regulatory loop

The axis is modulated through the inhibition of its individual components: BACE1 inhibitors block the rate-limiting step of amyloid-beta production; VEGF inhibitors neutralize circulating growth factors to prevent pathological angiogenesis; and HIF inhibitors prevent the transcriptional activation of downstream targets like BACE1 and VEGF under hypoxic conditions.